Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

4C Medical's AltaValve First In Human Experience to be Presented at TCT 2018

4C Medical Technologies,Inc.
Posted on: 13 Sep 18
4C Medical's AltaValve First In Human Experience to be Presented at TCT 2018

PR Newswire

BROOKLYN PARK, Minn., Sept. 13, 2018

BROOKLYN PARK, Minn., Sept. 13, 2018 /PRNewswire/ -- 4C Medical Technologies, Inc. (4C Medical), a developer of minimally invasive technologies for structural heart disease, today announced that its AltaValve™, a transcatheter mitral valve replacement (TMVR) technology, will be highlighted in the following presentations at the Transcatheter Cardiovascular Therapeutics (TCT) meeting held September 21-25, 2018 in San Diego, CA:

  • Friday, September 21, 2018, @ 3:45pm during Innovation Sessions:
    • "4C Medical's AltaValve: The First Human Experience" by Dr. Josep Rodés-Cabau
  • Sunday, September 23, 2018 @ 3:50pm during Edited Taped Cases:
    • "AltaValve TMVR" presented by Dr. Josep Rodés-Cabau
  • Monday, September 24, 2018 @ 10:12am during Didactic Session: Transcatheter Mitral Valve Therapies, Part 2 - TMVR:
    • "AltaValve: Device Attributes, Implant Procedure, and First-in-Human" presented by Dr. Philippe Généreux

Josep Rodés-Cabau, MD, is the Director of Catheterization and Interventional Laboratories in Quebec Heart and Lung Institute, Associate Professor of Medicine of Laval University and Canadian Research Chair "Fondation Famille Jacques Larivière" for the Development of Structural Heart Disease Interventions (Quebec City, Quebec, Canada).

Philippe Généreux, MD, is Co-Director of the Structural Heart Program at the Gagnon Cardiovascular Institute of Morristown Medical Center (Morristown, NJ) and a practicing Interventional Cardiologist at Hôpital du Sacré-Coeur de Montréal (Montreal, Canada).

In contrast with other TMVR devices, the AltaValve is the first mitral regurgitation (MR) treatment device that is placed in the left atrium, thus preserving the left ventricle. Furthermore, due to supra-annular positioning of the valve, AltaValve avoids issues related to the complexity and dynamics of the mitral annulus, making it suitable for patients independent of their MR mechanism. The AltaValve is a self-expanding device that may be inserted into the left atrium using either a transseptal or a transapical delivery system.

About 4C Medical Technologies, Inc.

4C Medical is a medical device company developing minimally invasive therapies for structural heart disease. Focusing initially on MR therapy and subsequently on tricuspid regurgitation therapy. The company's implant is the first MR therapy with supra-annular positioning and atrial-only fixation. It preserves the native mitral valve and left ventricle, eliminating known issues associated with TMVR technologies which rely on placement and fixation in the native mitral annulus and left ventricle.  


 Media Contacts:



Robert Thatcher

Chief Executive Officer

(612) 600-8951

rthatcher@4CMed.com

Jim Flaherty

Chief Financial Officer

(612) 599-0650

jflaherty@4CMed.com

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/4c-medicals-altavalve-first-in-human-experience-to-be-presented-at-tct-2018-300712048.html

SOURCE 4C Medical Technologies, Inc.

PR Newswire
www.prnewswire.com

Last updated on: 13/09/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.